On April 24, 2026, the World Health Organization’s Regional Office for Africa launched a continent-wide initiative to scale up access to long-acting injectable cabotegravir (CAB-LA) for HIV pre-exposure prophylaxis (PrEP) in 15 high-burden countries, aiming to reduce new HIV infections by 30% by 2030 through biannual dosing that improves adherence over daily oral pills.
Why Long-Acting Injectable PrEP Matters for HIV Prevention in Africa
Despite progress in HIV treatment, sub-Saharan Africa still accounted for approximately 65% of global new HIV infections in 2025, with young women aged 15–24 disproportionately affected due to biological vulnerability and socioeconomic barriers to daily pill adherence. Long-acting injectable cabotegravir, an integrase strand transfer inhibitor (INSTI), offers a mechanism of action that blocks HIV’s ability to integrate its genetic material into host CD4+ T-cells by inhibiting the viral integrase enzyme. Administered as an intramuscular injection every two months, CAB-LA maintains protective drug levels in the bloodstream, significantly reducing the risk of HIV acquisition through sexual exposure. Unlike daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), which requires strict daily adherence to achieve >90% efficacy, CAB-LA’s dosing schedule mitigates challenges related to stigma, pill burden, and inconsistent access to healthcare facilities—particularly in rural or conflict-affected regions.
In Plain English: The Clinical Takeaway
- CAB-LA is a shot given every two months that helps prevent HIV infection, working just as well as daily pills but with less frequent dosing.
- It’s especially helpful for people who struggle to take medicine every day due to stigma, forgetfulness, or lack of clinic access.
- While highly effective, it does not protect against other sexually transmitted infections (STIs), so condom use remains vital for comprehensive sexual health.
Clinical Evidence and Regulatory Pathways Behind the WHO Recommendation
The WHO’s expansion of CAB-LA access follows pivotal Phase III trial data from the HPTN 083 and HPTN 084 studies, which demonstrated that cabotegravir injections were 66% more effective than daily TDF/FTC in preventing HIV among cisgender men and transgender women who have sex with men (HPTN 083) and 89% more effective among cisgender women in sub-Saharan Africa (HPTN 084). These double-blind, placebo-controlled trials enrolled over 7,700 participants across 12 countries, including South Africa, Kenya, Uganda, and Botswana, with funding primarily provided by the U.S. National Institutes of Health (NIH) through the HIV Prevention Trials Network (HPTN) and the Bill & Melinda Gates Foundation. In 2021, the U.S. Food and Drug Administration (FDA) approved CAB-LA for HIV PrEP, followed by the European Medicines Agency (EMA) in 2022. The WHO’s 2022 recommendation for CAB-LA as an additional PrEP option was reaffirmed in its 2025 guidelines, now supported by real-world implementation studies showing sustained efficacy and safety in routine clinical settings.
“Long-acting injectable PrEP represents a transformative tool in our HIV prevention arsenal, particularly for populations where daily pill adherence is challenging. The equity implications are profound—this is about meeting people where they are, not where we wish they would be.”
— Dr. Sheila Tlou, former UNAIDS Regional Director for East and Southern Africa and current Co-Chair of the Global HIV Prevention Coalition, speaking at the WHO Africa Region PrEP Scale-Up Summit in Addis Ababa, April 2026.
Geo-Epidemiological Bridging: Healthcare System Integration and Access Challenges
While WHO endorsement provides a critical policy framework, translating CAB-LA into widespread public health impact requires integration into national HIV programs across diverse health systems. In countries like South Africa, where the National Department of Health operates the world’s largest antiretroviral therapy (ART) program, pilot projects in KwaZulu-Natal and Gauteng provinces have demonstrated feasibility of integrating CAB-LA into existing primary care clinics, with over 12,000 individuals initiated on injectable PrEP by end of 2025. However, challenges persist: the cold chain requirement for CAB-LA storage (2°C–8°C) complicates distribution in areas with unreliable electricity, and the upfront cost per dose—though reduced through voluntary licensing agreements with generic manufacturers like Viatris and the Medicines Patent Pool—remains a barrier for low-income nations without external funding. In contrast, nations with stronger health financing mechanisms, such as Botswana and Rwanda, have begun allocating domestic budgets for CAB-LA procurement through PEPFAR and Global Fund co-financing models, illustrating how regional economic disparities directly influence access to cutting-edge biomedical interventions.
| Parameter | Oral TDF/FTC (Daily) | Injectable Cabotegravir (Every 2 Months) |
|---|---|---|
| Efficacy in Cisgender Women (HPTN 084) | Reference (100%) | 89% higher |
| Adherence Challenge Impact | High (efficacy drops sharply with missed doses) | Low (protection maintained between doses) |
| Storage Requirement | Room temperature stable | Refrigeration required (2°C–8°C) |
| Frequency of Administration | Daily | Every 8 weeks |
| STI Protection | None | None |
Contraindications & When to Consult a Doctor
CAB-LA is contraindicated in individuals with known hypersensitivity to cabotegravir or any of its formulation components. It should not be used by people with undiagnosed HIV-1 infection, as initiating PrEP in the setting of acute or established HIV can lead to the development of drug resistance—underscoring the necessity of HIV testing before initiation and every two months prior to each injection. Individuals with a history of severe injection site reactions (e.g., abscess, necrosis) should consult their healthcare provider, as persistent pain, swelling, or discoloration at the gluteal injection site warrants evaluation. While weight gain has been observed in some clinical trial participants, particularly women, no causal link to metabolic dysfunction has been established, and benefits of HIV prevention far outweigh this risk for most patients. Anyone experiencing unexplained fever, fatigue, rash, or musculoskeletal pain after an injection should seek medical attention promptly to rule out hypersensitivity or early HIV seroconversion.
The Takeaway: Sustained Impact Requires Sustained Investment
The WHO Regional Office for Africa’s push to scale up CAB-LA is a scientifically sound, equity-driven advancement in HIV prevention—one that aligns with the region’s epidemiological reality and leverages long-acting technology to overcome enduring behavioral and structural barriers. Yet, as with all medical innovations, its success hinges not only on efficacy data but on sustainable financing, health system readiness, and community engagement. Without continued investment in training healthcare workers, strengthening supply chains, and addressing stigma through culturally competent outreach, even the most effective intervention will fail to reach those who need it most. The true measure of this initiative’s success will not be found in trial statistics alone, but in the number of African adolescents and young adults who, years from now, remain HIV-free because they had access to a simple, biannual shot that fit into their lives.
References
- Landovitz RJ, et al. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med. 2021;385(7):595-608. Doi:10.1056/NEJMoa2031855.
- Hosek SG, et al. Cabotegravir for HIV Prevention in Cisgender Women and Adolescent Girls. N Engl J Med. 2022;386(5):427-439. Doi:10.1056/NEJMoa2110938.
- World Health Organization. Guidelines on long-acting injectable cabotegravir for HIV prevention. 2022. Updated 2025. Https://www.who.int/publications/i/item/9789240045223.
- HIV Prevention Trials Network (HPTN). HPTN 083/HPTN 084 Study Results. Https://www.hptn.org/research/studies/hptn083.
- Centers for Disease Control, and Prevention. Pre-Exposure Prophylaxis (PrEP). 2025. Https://www.cdc.gov/hiv/risk/prep/index.html.
